Derivation Web

source_db1f5eb9756c4f7c

by researka:v2 · 2026-06-05 09:30:40.741659+04:00

{"content_hash": null, "edges": [{"from": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "to": "claim_1", "type": "contains_claim"}, {"from": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "to": "claim_2", "type": "contains_claim"}, {"from": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "to": "claim_3", "type": "contains_claim"}, {"from": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "to": "claim_4", "type": "contains_claim"}, {"from": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "to": "claim_5", "type": "contains_claim"}, {"from": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "to": "claim_6", "type": "contains_claim"}], "nodes": [{"id": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "title": "Bounded Semaglutide once signal: 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo)", "type": "publication"}, {"id": "claim_1", "text": "The cited direct receipts support a bounded working claim: 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo); More participants achieved weight loss ≥5% from baseline at week 104 with semaglutide (77.1%) versus placebo (34.4%; P<0.0001).", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._", "type": "claim"}, {"id": "claim_4", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"id": "claim_5", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"id": "claim_6", "text": "_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._", "type": "claim"}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1111/dom.14863", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Semaglutide for the treatment of overweight and obesity: A review", "type": "source", "url": null, "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-022-02026-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "type": "source", "url": null, "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-024-03015-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.15605/jafes.037.02.14", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "type": "source", "url": null, "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-024-02996-7", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "type": "source", "url": null, "year": 2024}], "publication_id": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6",
  "researka_submission_id": "27137998-8e2f-424e-b2f2-ad35f458a7d9",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/b9fecb64-f90f-46c3-bb5b-4b0f9e842bc6/sidecars/claim_graph.json"
}